Analysis of the effect of thyroxine replacement therapy on children with SES after cardiac surgery

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000034223

Enrollment

Unknown

Registered

2020-06-28

Start date

2020-07-01

Completion date

Unknown

Last updated

2020-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital heart disease

Interventions

control group:placebo oral

Experimental group:The thyroxine tablets were taken orally once a day for 2 weeks

Eligibility

Sex/Gender

All

Age

No minimum to 3 Years

Inclusion criteria

Inclusion criteria: (1) Children with congenital heart disease whose age is less than 6 months and weight is less than 6 kg; (2) preoperative thyroid function (total T3, FT3, T4, FT4, TSH) is normal.

Exclusion criteria

Exclusion criteria: (1) There are other system deformities; (2) liver and kidney dysfunction; (3) thyroxine drugs and iodine preparation.

Design outcomes

Primary

Measure	Time frame
Thyroid function (TT3, FT3, TT4, FT4, TSH);	—

Secondary

Measure	Time frame
Intubation time;ICU stay time;hospital stay;Postoperative complications;30-day mortality;	—

Countries

China

Contacts

Public ContactLiang Zou

Children's Hospital of Nanjing Medical University

85225151@qq.com+86 18652931463

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026